GIP/GLP-1 dual agonist
The drug class tirzepatide belongs to: it activates both the GLP-1 receptor and the GIP receptor, versus semaglutide’s GLP-1-only mechanism — the pharmacological basis for the efficacy gap measured in the SURMOUNT-5 head-to-head, and part of why tirzepatide prices carry a premium in every lane.
Updated 2026-08-10 · figures captured 2026-08-09 · how we verify
Where the term bites in the current data: the verified tirzepatide field runs $215–$597/month all-in and the semaglutide field $133–$348 (captured 2026-08-09), and nearly every dollar of those spreads is explained by the vocabulary on this glossary’s pages — memberships inside or outside headline figures, flat versus tiered ladders, prepaid terms dressed as monthly prices, evidence flags separating captures from claims. Reading this market is mostly a matter of knowing which of those words applies to the number in front of you.
Like every entry here, this definition is written against the live dataset rather than in the abstract: when the market moves, the interpolated figures in this glossary move with it on the next build, which is the only way definitions about a repricing market stay true.
See the term in action across the price database and the methodology.